Amount of qualified clients: CDEC reviewed the uncertainty in the volume of sufferers with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are classified as having moderate or moderate illness may have a severe bleeding ph